4.3514
price down icon2.43%   -0.1686
 
loading
前日終値:
$4.52
開ける:
$4.46
24時間の取引高:
89,192
Relative Volume:
0.06
時価総額:
$144.88M
収益:
-
当期純損益:
$-29.25M
株価収益率:
-3.773
EPS:
-1.1533
ネットキャッシュフロー:
$-22.80M
1週間 パフォーマンス:
-14.86%
1か月 パフォーマンス:
-20.83%
6か月 パフォーマンス:
-7.93%
1年 パフォーマンス:
+36.11%
1日の値動き範囲:
Value
$4.36
$4.61
1週間の範囲:
Value
$4.19
$5.18
52週間の値動き範囲:
Value
$2.39
$20.71

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name
名前
Sagimet Biosciences Inc
Name
セクター
Healthcare (1195)
Name
電話
(650) 561-8600
Name
住所
155 BOVET RD., SUITE 303, SAN MATEO
Name
職員
10
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
SGMT's Discussions on Twitter

SGMT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
SGMT 4.37 144.88M 0 -29.25M -22.80M -1.1533
VRTX 446.82 115.74B 10.63B -479.80M -1.35B 13.33
REGN 738.18 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 585.10 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.38 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.30 24.49B 3.30B -501.07M 1.03B 11.54

Sagimet Biosciences Inc (SGMT) 最新ニュース

pulisher
Nov 19, 2024

Sagimet Biosciences participates ik,on No - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences keeps stock target with Buy rating on phase 3 program - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences Presents Clinical Denifanstat and - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDThe Liver Meeting® 2024 - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet's Denifanstat Shows 49% Fibrosis Improvement in Phase 2b MASH Trial | SGMT Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance

Nov 18, 2024
pulisher
Nov 16, 2024

Sagimet Biosciences (NASDAQ:SGMT) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Steven Cohen's Strategic Acquisition in Sagimet Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Hillhouse Capital Management's Strategic Reduction in Sagimet Bi - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Baker Bros. Advisors LP Increases Stake in Sagimet Biosciences I - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $24.00 Consensus Price Target from Analysts - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences Advances MASH Treatment with Denifanstat - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet: More Than Just A MASH Drug Development Biotech (NASDAQ:SGMT) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences reports Q3 EPS (45c) vs (35c) last year - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 13, 2024

Ascletis Completes Enrollment of Phase III Trial of ASC40 Once-Daily Oral Tablet for Treatment of Acne - Marketscreener.com

Nov 13, 2024
pulisher
Nov 12, 2024

UBS says Sagimet stock could steal the MASH spotlight from injectables - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Sagimet stock draws buy at UBS on MASH(SGMT:NASDAQ) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

SGMTSagimet Biosciences Inc. Series A Latest Stock News & Market Updates - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) Price Target at $24.00 - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS Group - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Sagimet Biosciences initiated with a Buy at UBS - TipRanks

Nov 12, 2024
pulisher
Nov 10, 2024

Sagimet Biosciences Insiders Benefit From Selling Stock At US$3.10 - Simply Wall St

Nov 10, 2024
pulisher
Nov 08, 2024

Trend Tracker for (SGMT) - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 07, 2024

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference - The Manila Times

Nov 07, 2024
pulisher
Nov 04, 2024

Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD - Liver Disease News

Nov 04, 2024
pulisher
Oct 31, 2024

HC Wainwright Reaffirms "Buy" Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Sagimet’s denifanstat enters Phase III trials for MASH treatment - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of End-Of-Phase 2 Interactions with Fda on the Development of Denifanstat for Mash - Marketscreener.com

Oct 29, 2024
pulisher
Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 - The Manila Times

Oct 29, 2024
pulisher
Oct 28, 2024

(SGMT) Technical Data - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 26, 2024

Sagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Update - MarketBeat

Oct 26, 2024
pulisher
Oct 18, 2024

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha

Oct 18, 2024
pulisher
Oct 18, 2024

(SGMT) Investment Analysis and Advice - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 16, 2024

There is no way Sagimet Biosciences Inc (SGMT) can keep these numbers up - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

Market Highlights: Sagimet Biosciences Inc (SGMT) Ends on a Low Note at 5.13 - The Dwinnex

Oct 16, 2024
pulisher
Oct 16, 2024

Sagimet Biosciences Announces Upcoming Presentations at AASLDThe Liver Meeting® 2024 - GlobeNewswire

Oct 16, 2024
pulisher
Oct 15, 2024

How to interpret Sagimet Biosciences Inc (SGMT)’s stock chart patterns - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Sagimet Biosciences Inc’s Shares Reel: 42.19% Quarterly Revenue Decline Amid 167.12M Market Cap - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

SGMT (Sagimet Biosciences Inc) may reap gains as insiders became active recently - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in the Lancet Gastroenterology and Hepatology - Marketscreener.com

Oct 14, 2024
pulisher
Oct 11, 2024

Sagimet Gains on Latest Numbers - Baystreet.ca

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet's denifanstat shows promise in Phase 2b MASH trial - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet's denifanstat shows promise in Phase 2b MASH trial By Investing.com - Investing.com UK

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial - The Bakersfield Californian

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from - GlobeNewswire

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - StockTitan

Oct 11, 2024

Sagimet Biosciences Inc (SGMT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Sagimet Biosciences Inc (SGMT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Martins Eduardo Bruno
Chief Medical Officer
Jul 19 '24
Sale
3.10
8,357
25,910
81,213
Rozek Elizabeth
General Counsel and CCO
Jul 19 '24
Sale
3.10
10,914
33,830
160,506
Kemble George
Executive Chairman
Jul 19 '24
Sale
3.10
14,062
43,605
142,318
Happel David
President & CEO
Mar 26 '24
Buy
5.27
12,100
63,731
639,200
Happel David
President & CEO
Dec 07 '23
Buy
4.10
1,600
6,560
627,100
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):